Found: 22
Select item for more details and to access through your institution.
Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers.
- Published in:
- Vaccines, 2024, v. 12, n. 2, p. 153, doi. 10.3390/vaccines12020153
- By:
- Publication type:
- Article
Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA).
- Published in:
- Vaccines, 2024, v. 12, n. 1, p. 15, doi. 10.3390/vaccines12010015
- By:
- Publication type:
- Article
The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses.
- Published in:
- Vaccines, 2023, v. 11, n. 2, p. 286, doi. 10.3390/vaccines11020286
- By:
- Publication type:
- Article
Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen.
- Published in:
- Vaccines, 2021, v. 9, n. 9, p. 959, doi. 10.3390/vaccines9090959
- By:
- Publication type:
- Article
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
- Published in:
- Vaccines, 2021, v. 9, n. 3, p. 243, doi. 10.3390/vaccines9030243
- By:
- Publication type:
- Article
Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus.
- Published in:
- Vaccines, 2019, v. 7, n. 3, p. 57, doi. 10.3390/vaccines7030057
- By:
- Publication type:
- Article
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141456
- By:
- Publication type:
- Article
Deletion of the Vaccinia Virus Gene <i>A46R</i>, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074831
- By:
- Publication type:
- Article
Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens.
- Published in:
- PLoS ONE, 2012, v. 7, n. 10, p. 1, doi. 10.1371/journal.pone.0048524
- By:
- Publication type:
- Article
High Quality Long-Term CD4<sup>+</sup> and CD8<sup>+</sup> Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection.
- Published in:
- PLoS ONE, 2012, v. 7, n. 6, p. 1, doi. 10.1371/journal.pone.0038859
- By:
- Publication type:
- Article
Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C.
- Published in:
- PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0035485
- By:
- Publication type:
- Article
Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens.
- Published in:
- PLoS ONE, 2010, v. 5, n. 6, p. 1, doi. 10.1371/journal.pone.0011406
- By:
- Publication type:
- Article
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
- Published in:
- Frontiers in Immunology, 2019, v. 10, p. 1, doi. 10.3389/fimmu.2019.02941
- By:
- Publication type:
- Article
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1270908
- By:
- Publication type:
- Article
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1160065
- By:
- Publication type:
- Article
An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses.
- Published in:
- Frontiers in Cellular & Infection Microbiology, 2023, p. 1, doi. 10.3389/fcimb.2023.1187193
- By:
- Publication type:
- Article
A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
- Published in:
- Viruses (1999-4915), 2019, v. 11, n. 2, p. 160, doi. 10.3390/v11020160
- By:
- Publication type:
- Article
Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
- Published in:
- Viruses (1999-4915), 2018, v. 10, n. 8, p. 424, doi. 10.3390/v10080424
- By:
- Publication type:
- Article
Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.
- Published in:
- Viruses (1999-4915), 2018, v. 10, n. 1, p. 7, doi. 10.3390/v10010007
- By:
- Publication type:
- Article
Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector.
- Published in:
- Virology Journal, 2008, v. 5, p. 1, doi. 10.1186/1743-422X-5-102
- By:
- Publication type:
- Article
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0186602
- By:
- Publication type:
- Article